Evidence map›Paper›PMID 38109686›Full record

ArticleAngewandte Chemie (International ed. in English)2024

Optical Control of Proteasomal Protein Degradation with a Photoswitchable Lipopeptide.

Johannes Morstein, Alexander Amatuni, Anton Shuster, Wolfgang Kuttenlochner, Tongil Ko, Daniel Abegg, Michael Groll, Alexander Adibekian, Hans Renata, Dirk H Trauner

Open access · bronzeAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Johannes MorsteinDepartment of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, San Francisco, CA-94158, USA.
Alexander AmatuniSkaggs Doctoral Program in the Chemical and Biological Sciences, Scripps Research, La Jolla, CA-92037, USA.
Anton ShusterSkaggs Doctoral Program in the Chemical and Biological Sciences, Scripps Research, La Jolla, CA-92037, USA.
Wolfgang KuttenlochnerTechnical University of Munich, TUM School of Natural Sciences, Department of Bioscience, Center for Protein Assemblies, Chair of Biochemistry, Ernst-Otto-Fischer-Str. 8, 85748, Garching, Germany.
Tongil KoDepartment of Chemistry, New York University, New York, NY-10003, USA.
Daniel AbeggDepartment of Chemistry, University of Illinois Chicago, Chicago, IL-60607, USA.
Michael GrollTechnical University of Munich, TUM School of Natural Sciences, Department of Bioscience, Center for Protein Assemblies, Chair of Biochemistry, Ernst-Otto-Fischer-Str. 8, 85748, Garching, Germany.
Alexander AdibekianDepartment of Chemistry, University of Illinois Chicago, Chicago, IL-60607, USA.
Hans RenataDepartment of Chemistry, BioScience Research Collaborative, Rice University, Houston, TX-77005, USA.
Dirk H TraunerDepartment of Chemistry, New York University, New York, NY-10003, USA.ORCID 0000-0002-6782-6056
New York University · USScripps Research Institute · USTechnical University of Munich · DEUniversity of Illinois Chicago · USHoward Hughes Medical Institute · USRice University · US

Funding

Biocatalytic C-H Functionalization Logic in the Chemoenzymatic Synthesis of Therapeutic Natural ProductsR35GM128895 · NIGMS · UNIVERSITY OF FLORIDA · PI Hans Renata · 2018 to 2026
$3.7M
Optical Control of the Actin CytoskeletonR01GM126228 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI DIRK HARTWIG TRAUNER · 2018 to 2026
$2.6M
Probing conformational changes by protein surface azidationR01GM145886 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ADIBEKIAN, ALEXANDER · 2022 to 2025
$1.6M
Targeting Cancer at the Protein-Membrane InterfaceK99CA277358 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORSTEIN, JOHANNES · 2023 to 2024
$326k
NCI NIH HHS K99 CA277358NCI NIH HHS K99CA277358NIGMS NIH HHS R01 GM126228NIGMS NIH HHS R01 GM145886NIGMS NIH HHS R35 GM128895NIH HHS R01GM126228NIH HHS R01GM145886NIH HHS R35GM128895
6 · The paper itself

Abstract

Photolipids have emerged as attractive tools for the optical control of lipid functions. They often contain an azobenzene photoswitch that imparts a cis double-bond upon irradiation. Herein, we present the application of photoswitching to a lipidated natural product, the potent proteasome inhibitor cepafungin I. Several azobenzene-containing lipids were attached to the cyclopeptide core, yielding photoswitchable derivatives. Most notably, PhotoCep4 exhibited a 10-fold higher cellular potency in its light-induced cis-form, matching the potency of natural cepafungin I. The length of the photolipid tail and distal positioning of the azobenzene photoswitch with respect to the macrocycle is critical for this activity. In a proteome-wide experiment, light-triggered PhotoCep4 modulation showed high overlap with constitutively active cepafungin I. The mode of action was studied using crystallography and revealed an identical binding of the cyclopeptide in comparison to cepafungin I, suggesting that differences in their cellular activity originate from switching the tail structure. The photopharmacological approach described herein could be applicable to many other natural products as lipid conjugation is common and often necessary for potent activity. Such lipids are often introduced late in synthetic routes, enabling facile chemical modifications.

Indexed as

Azo CompoundsLipopeptidesPeptides, CyclicProteolysisazobenzeneAzo CompoundsLipopeptidesPeptides, CyclicLipopeptideNatural ProductsPhotopharmacologyPhotoswitchProteasome

Identifiers

PMID38109686
PMCPMC12079555
OpenAlexW4389887416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.